Genprex合作研究团队于2026年美国癌症研究协会（AACR）年会期间，展示了其核心候选药物Reqorsa®基因疗法在肺癌治疗领域的突破性临床前研究结果。数据显示，该基因疗法在临床前模型中表现出显著的抗肿瘤活性与良好安全性特征，为后续临床开发提供了有力支持。
Genprex合作研究团队于2026年美国癌症研究协会（AACR）年会期间，展示了其核心候选药物Reqorsa®基因疗法在肺癌治疗领域的突破性临床前研究结果。数据显示，该基因疗法在临床前模型中表现出显著的抗肿瘤活性与良好安全性特征，为后续临床开发提供了有力支持。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.